Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at the American Academy of Optometry 2022 Annual Meeting - Seite 3

In addition to the risks described above and in Aldeyra's other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra's results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

¹ The American Academy of Allergy, Asthma & Immunology (AAAAI), Allergic Conjunctivitis Defined
² Andrew D. Pitt, Andrew F. Smith, Lynda Lindsell, Li Wern Voon, Peter W. Rose & Anthony J. Bron (2004) Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire, Ophthalmic Epidemiology, 11:1, 17-33, doi: 10.1076/opep.11.1.17.26437
³ Leonardi A, Piliego F, Castegnaro A, et al. Allergic conjunctivitis: a cross-sectional study. Clin Exp Allergy. 2015;45(6):1118–1125. doi:10.1111/cea.12536

View source version on businesswire.com: https://www.businesswire.com/news/home/20221024006055/en/

The Aldeyra Therapeutics Stock at the time of publication of the news with a raise of +0,38 % to 5,282EUR on Tradegate stock exchange (25. Oktober 2022, 22:27 Uhr).